The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
How should novel agents be used in the current treatment pathways for GvHD?
Mohamad Mohty
Florent Malard
Arnon Nagler
Amin Alousi
Hildegard GreinixDuring the GvHD Hub Steering Committee meeting on April 5, 2022, key opinion leaders met to debate the question of how novel agents should be used in the current treatment pathways for GvHD. This recorded discussion was chaired by Amin Alousi, and featured Hildegard Greinix, Mohamad Mohty, Florent Malard, and Arnon Nagler.
How should novel agents be used in the current treatment pathways for GvHD?
Alousi begins the discussion by asking which approaches are commonly used by the steering committee members to sequence therapies for GvHD. Greinix mentions the challenge of working in Europe due ROCK inhibitors not yet being approved. The steering committee talk about the use of ruxolitinib and ibrutinib, as well as steroid tapering schedules. They also discuss when to describe GvHD as refractory and consider the impact of cumulative exposure to steroids.